Schedule of Pharmaceutical Benefits - 1 August 2015

PBAC

1 August 2025 - The August 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The August issue of the Schedule includes has a few new/revised listings of note: 

  • Denosumab (Wyost, Jubbonti) - new biosimilar medicine
  • Durvalumab (Imfinzi) - new indication
  • Eflornithine hydrochloride monohydrate (Ifinwil) - new medicine
  • Foslevodopa with foscarbidopa (Vyalev) - new combination product
  • Omalizumab (Omlyco) - new biosimilar medicine
  • Omalizumab (Xolair) - new formulation
  • Ustekinumab (Steqeyma) - new biosimilar medicine

Read summary of PBS changes

Michael Wonder

Posted by:

Michael Wonder